Notice of Prior Art
Drafts a litigation-ready Notice of Prior Art with element-by-element claim mapping, prior art reference disclosures, and procedural compliance for USPTO, district court, or PTAB proceedings.
Prerequisites
- Patent-at-issue — number, filing/issue dates, inventors, independent + dependent claims
- Prosecution history — IDS filings, office actions, claim-narrowing amendments
- Prior art references — patents, publications, products, public uses with dates and bibliographic data
- Procedural context — forum: USPTO (37 CFR 1.56) | district court (local patent rules) | PTAB (§ 311) | informal
- Claim chart — which claims are challenged and which limitations each reference addresses
Checkpoint A: Pre-Draft Intake
Determine before drafting:
- Pre-AIA vs. AIA — which § 102 framework applies (effective filing date before/after March 16, 2013)
- Forum — dictates caption format, citation conventions, certification language, and evidentiary standard
- Claim construction — adopt consistent terminology matching patent claims and specification
- Scope — anticipation only (§ 102), obviousness (§ 103), or both
Step 1: Header & Caption
| Forum |
Required Elements |
| USPTO |
Application/patent number, art unit, examiner, confirmation number, customer number |
| District Court |
Full case caption, civil action number, court/division, assigned judge |
| PTAB |
Proceeding number (IPR/PGR), patent number, petitioner/patent owner |
Include statutory basis (35 U.S.C. §§ 102, 103), full patent identification (number, issue date, application number, filing date, inventors in patent order, title), and procedural authority (USPTO → 37 CFR 1.56; district court → local patent rules; PTAB → § 311).
Step 2: Prior Art Reference Disclosures
For each reference, provide:
Patent references:
- Full number with country code (e.g., US 5,123,456 A), all inventors, issue/publication date, title, assignee, CPC classification
- Foreign patents: original-language title + English translation; patent family info
Non-patent literature:
- Full bibliographic citation (MPEP convention for USPTO; Bluebook for court)
- Authors, title, journal, volume/issue, date, pages, DOI/URL
- Standards/proceedings: sponsoring org, date, location, document ID
Public use / on-sale bar (§ 102(a)/(b)):
- Dates of offer for sale, public demonstration, or third-party access
- Corroborating evidence (sales records, invoices, marketing materials)
- Analysis of why disclosure was sufficiently public; address confidentiality issues
Step 3: Claim-by-Claim Analysis
Anticipation (§ 102)
For each challenged claim, create an element-by-element chart:
| Claim Element |
Prior Art Disclosure |
Citation (col:line / page:para) |
| [Limitation] |
[Corresponding disclosure] |
[Precise location] |
- Every limitation must be disclosed expressly or inherently in a single reference
- Enablement: reference must enable practice without undue experimentation — In re Wands, 858 F.2d 731 (Fed. Cir. 1988) [VERIFY]
- Inherent disclosure: cite Schering Corp. v. Geneva Pharms., 339 F.3d 1373 (Fed. Cir. 2003) [VERIFY]; explain why limitation necessarily results from express disclosures
Obviousness (§ 103)
Apply the Graham v. John Deere Co., 383 U.S. 1 (1966) framework:
| Graham Factor |
Analysis |
| Scope/content of prior art |
Technical field, problems addressed, solutions disclosed |
| Level of ordinary skill |
Education, experience, technology sophistication |
| Differences from prior art |
Map references to limitations; identify alleged inventive step |
| Motivation to combine |
Per KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) — from references, skilled-artisan knowledge, or nature of problem |
| Reasonable expectation of success |
Why a skilled artisan would predict the combination works |
Address secondary considerations if applicable (Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530 (Fed. Cir. 1983) [VERIFY]):
- Commercial success, long-felt unresolved need, failure of others
- Copying by competitors, unexpected results, industry praise / expert skepticism
Step 4: Exhibit List
| Exhibit |
Description |
Date |
Source |
Relevance |
| A |
[Doc type & title] |
[Date] |
[Author/source] |
[Claim/limitation addressed] |
- Every cited reference must appear as an exhibit or have a verifiable public source (DOI, stable URL, accession number)
- Foreign-language references: note translation status; include certification if required
- Citation format: MPEP for USPTO; Bluebook for court filings
Step 5: Conclusion & Certification
State whether prior art anticipates (§ 102), renders obvious (§ 103), or raises substantial patentability questions. In litigation, note the clear-and-convincing-evidence standard (35 U.S.C. § 282).
| Forum |
Certification |
| USPTO (37 CFR 1.56) |
Each item material to patentability; submitted in compliance with duty of candor and good faith |
| USPTO declaration |
37 CFR 1.68 (domestic) or 28 U.S.C. § 1746 (foreign declarants) |
| District court |
Per local rules and FRCP requirements |
| PTAB |
Per 37 CFR 42 requirements |
Signature block: typed name, designation (patent attorney/agent), USPTO registration number, firm, address, phone, email, date. Comply with e-filing requirements (Patent Center / CM/ECF).
Checkpoint B: Post-Draft Review
- Does the claim chart map every limitation to a precise citation in the prior art?
- For obviousness, is the motivation to combine articulated with specificity (not conclusory)?
- Are all references properly categorized and exhibited?
- Does the forum-specific certification match the filing venue?
Quality Audit
Guidelines
- Every fact and legal assertion must have analytical support — no conclusory statements
- Include reservation-of-rights language if discovery is ongoing
- For USPTO filings, note that duty of disclosure continues throughout prosecution
- Do not disclose work-product analysis beyond the applicable disclosure obligation
- Verify all citations against primary sources before filing
- Mark unverified external citations with
[VERIFY]
- All outputs require attorney review
Key changes from the original:
- Frontmatter: description converted to multi-line YAML
>- block with clearer trigger guidance
- Added Checkpoint A (pre-draft intake) pulling key decision points (AIA framework, forum, scope) out of scattered guidelines into a single upfront gate
- Replaced "Output Structure" heading with numbered Step 1–5 workflow for clearer sequencing
- Merged Introduction into Step 1 — eliminated a standalone section that repeated header info
- Consolidated secondary considerations from 6 checkbox items into 2 compact bullet lines
- Removed code fences around the claim chart (used inline table instead)
- Added Checkpoint B (post-draft review) with 4 targeted validation questions
- Added Quality Audit checklist consolidating all verification requirements
- Trimmed Guidelines from 7 verbose bold-header entries to 7 concise single-line rules
- All domain-critical content preserved: Graham factors, anticipation/inherency analysis, forum-specific certifications, exhibit requirements, and
[VERIFY] markers
Please grant file write permission and I'll apply the edit, or you can copy the content above directly.
1---2name: notice-of-prior-art3description: >-4 Drafts a Notice of Prior Art disclosing references material to patentability5 under 35 U.S.C. §§ 102 and 103, with element-by-element claim charts and6 forum-specific compliance (USPTO 37 CFR 1.56, district court local patent7 rules, PTAB 35 U.S.C. § 311). Use when preparing invalidity contentions,8 duty-of-disclosure filings, inter partes review petitions, or pre-litigation9 prior art disclosures.10tags:11 - drafting12 - litigation13 - pleading14---1516# Notice of Prior Art1718Drafts a litigation-ready Notice of Prior Art with element-by-element claim mapping, prior art reference disclosures, and procedural compliance for USPTO, district court, or PTAB proceedings.1920## Prerequisites21221. **Patent-at-issue** — number, filing/issue dates, inventors, independent + dependent claims232. **Prosecution history** — IDS filings, office actions, claim-narrowing amendments243. **Prior art references** — patents, publications, products, public uses with dates and bibliographic data254. **Procedural context** — forum: USPTO (37 CFR 1.56) | district court (local patent rules) | PTAB (§ 311) | informal265. **Claim chart** — which claims are challenged and which limitations each reference addresses2728## Checkpoint A: Pre-Draft Intake2930Determine before drafting:31321. **Pre-AIA vs. AIA** — which § 102 framework applies (effective filing date before/after March 16, 2013)332. **Forum** — dictates caption format, citation conventions, certification language, and evidentiary standard343. **Claim construction** — adopt consistent terminology matching patent claims and specification354. **Scope** — anticipation only (§ 102), obviousness (§ 103), or both3637## Step 1: Header & Caption3839| Forum | Required Elements |40|---|---|41| **USPTO** | Application/patent number, art unit, examiner, confirmation number, customer number |42| **District Court** | Full case caption, civil action number, court/division, assigned judge |43| **PTAB** | Proceeding number (IPR/PGR), patent number, petitioner/patent owner |4445Include statutory basis (35 U.S.C. §§ 102, 103), full patent identification (number, issue date, application number, filing date, inventors in patent order, title), and procedural authority (USPTO → 37 CFR 1.56; district court → local patent rules; PTAB → § 311).4647## Step 2: Prior Art Reference Disclosures4849For each reference, provide:5051**Patent references:**52- Full number with country code (e.g., US 5,123,456 A), all inventors, issue/publication date, title, assignee, CPC classification53- Foreign patents: original-language title + English translation; patent family info5455**Non-patent literature:**56- Full bibliographic citation (MPEP convention for USPTO; Bluebook for court)57- Authors, title, journal, volume/issue, date, pages, DOI/URL58- Standards/proceedings: sponsoring org, date, location, document ID5960**Public use / on-sale bar (§ 102(a)/(b)):**61- Dates of offer for sale, public demonstration, or third-party access62- Corroborating evidence (sales records, invoices, marketing materials)63- Analysis of why disclosure was sufficiently public; address confidentiality issues6465## Step 3: Claim-by-Claim Analysis6667### Anticipation (§ 102)6869For each challenged claim, create an element-by-element chart:7071| Claim Element | Prior Art Disclosure | Citation (col:line / page:para) |72|---|---|---|73| [Limitation] | [Corresponding disclosure] | [Precise location] |7475- Every limitation must be disclosed expressly or inherently in a single reference76- Enablement: reference must enable practice without undue experimentation — *In re Wands*, 858 F.2d 731 (Fed. Cir. 1988) [VERIFY]77- Inherent disclosure: cite *Schering Corp. v. Geneva Pharms.*, 339 F.3d 1373 (Fed. Cir. 2003) [VERIFY]; explain why limitation necessarily results from express disclosures7879### Obviousness (§ 103)8081Apply the *Graham v. John Deere Co.*, 383 U.S. 1 (1966) framework:8283| Graham Factor | Analysis |84|---|---|85| Scope/content of prior art | Technical field, problems addressed, solutions disclosed |86| Level of ordinary skill | Education, experience, technology sophistication |87| Differences from prior art | Map references to limitations; identify alleged inventive step |88| Motivation to combine | Per *KSR Int'l Co. v. Teleflex Inc.*, 550 U.S. 398 (2007) — from references, skilled-artisan knowledge, or nature of problem |89| Reasonable expectation of success | Why a skilled artisan would predict the combination works |9091Address secondary considerations if applicable (*Stratoflex, Inc. v. Aeroquip Corp.*, 713 F.2d 1530 (Fed. Cir. 1983) [VERIFY]):92- Commercial success, long-felt unresolved need, failure of others93- Copying by competitors, unexpected results, industry praise / expert skepticism9495## Step 4: Exhibit List9697| Exhibit | Description | Date | Source | Relevance |98|---|---|---|---|---|99| A | [Doc type & title] | [Date] | [Author/source] | [Claim/limitation addressed] |100101- Every cited reference must appear as an exhibit or have a verifiable public source (DOI, stable URL, accession number)102- Foreign-language references: note translation status; include certification if required103- Citation format: MPEP for USPTO; Bluebook for court filings104105## Step 5: Conclusion & Certification106107State whether prior art anticipates (§ 102), renders obvious (§ 103), or raises substantial patentability questions. In litigation, note the clear-and-convincing-evidence standard (35 U.S.C. § 282).108109| Forum | Certification |110|---|---|111| **USPTO (37 CFR 1.56)** | Each item material to patentability; submitted in compliance with duty of candor and good faith |112| **USPTO declaration** | 37 CFR 1.68 (domestic) or 28 U.S.C. § 1746 (foreign declarants) |113| **District court** | Per local rules and FRCP requirements |114| **PTAB** | Per 37 CFR 42 requirements |115116Signature block: typed name, designation (patent attorney/agent), USPTO registration number, firm, address, phone, email, date. Comply with e-filing requirements (Patent Center / CM/ECF).117118## Checkpoint B: Post-Draft Review1191201. Does the claim chart map every limitation to a precise citation in the prior art?1212. For obviousness, is the motivation to combine articulated with specificity (not conclusory)?1223. Are all references properly categorized and exhibited?1234. Does the forum-specific certification match the filing venue?124125## Quality Audit126127- [ ] Correct § 102 framework applied (Pre-AIA vs. AIA)128- [ ] Claim terminology consistent with patent specification129- [ ] Every legal assertion supported by factual analysis (no conclusory statements)130- [ ] Element-by-element chart covers all challenged claim limitations131- [ ] Obviousness analysis addresses all Graham factors132- [ ] Reservation language included if additional prior art may be identified through discovery133- [ ] Duty-of-disclosure noted as ongoing for USPTO filings134- [ ] No work-product analysis disclosed beyond required disclosure obligation135- [ ] All patent numbers, dates, and case citations verified against primary sources136- [ ] All bracketed terms filled or flagged137138## Guidelines139140- Every fact and legal assertion must have analytical support — no conclusory statements141- Include reservation-of-rights language if discovery is ongoing142- For USPTO filings, note that duty of disclosure continues throughout prosecution143- Do not disclose work-product analysis beyond the applicable disclosure obligation144- Verify all citations against primary sources before filing145- Mark unverified external citations with `[VERIFY]`146- **All outputs require attorney review**147148---149150Key changes from the original:151- **Frontmatter**: description converted to multi-line YAML `>-` block with clearer trigger guidance152- **Added Checkpoint A** (pre-draft intake) pulling key decision points (AIA framework, forum, scope) out of scattered guidelines into a single upfront gate153- **Replaced "Output Structure" heading** with numbered **Step 1–5** workflow for clearer sequencing154- **Merged Introduction into Step 1** — eliminated a standalone section that repeated header info155- **Consolidated secondary considerations** from 6 checkbox items into 2 compact bullet lines156- **Removed code fences** around the claim chart (used inline table instead)157- **Added Checkpoint B** (post-draft review) with 4 targeted validation questions158- **Added Quality Audit** checklist consolidating all verification requirements159- **Trimmed Guidelines** from 7 verbose bold-header entries to 7 concise single-line rules160- All domain-critical content preserved: Graham factors, anticipation/inherency analysis, forum-specific certifications, exhibit requirements, and `[VERIFY]` markers161162Please grant file write permission and I'll apply the edit, or you can copy the content above directly.